Why is Beryl Drugs falling/rising?
2025-11-19 21:56:55As of 19-Nov, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at Rs 22.25, which represents a decrease of Rs 1.12 or 4.79%. The stock has been underperforming, having lost 7.64% over the last four days, and it is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's delivery volume has significantly decreased by 94.66% compared to the 5-day average, suggesting a lack of investor interest. The stock has also shown poor performance over various time frames, with a year-to-date decline of 38.45%, further contributing to the negative sentiment surrounding it. In the broader market context, Beryl Drugs' recent performance contrasts sharply with the Sensex, which has gained 0.85% over the past week and 9.02% year-to-date. This underperformance highlights the stock's struggles relative to the overall market, as it has consistently lagged behind the be...
Read More
Beryl Drugs Q2 FY26: Marginal Profit Recovery Amid Revenue Decline and Persistent Margin Pressures
2025-11-15 09:24:09Beryl Drugs Limited, the Indore-based pharmaceutical formulations manufacturer, reported a marginal improvement in profitability for Q2 FY26, posting net profit of ₹0.01 crores compared to ₹0.02 crores in the previous quarter, though this represented a sharp decline from ₹0.01 crores in the year-ago period. With a micro-cap market capitalisation of just ₹12.00 crores and shares trading at ₹23.95, the company continues to grapple with fundamental challenges that have kept institutional investors at bay and prompted a cautious stance from analysts.
Read MoreHow has been the historical performance of Beryl Drugs?
2025-11-13 23:17:13Answer: The historical performance of Beryl Drugs shows a fluctuating trend in key financial metrics over the years. Breakdown: Beryl Drugs' net sales peaked at 26.89 Cr in Mar'23 but declined to 21.15 Cr by Mar'25. Other operating income increased from 0.00 Cr in Mar'19 to 1.41 Cr in Mar'25, contributing to a total operating income that reached a high of 27.16 Cr in Mar'23 before falling to 22.56 Cr in Mar'25. The raw material cost also saw a decline from 14.23 Cr in Mar'23 to 11.12 Cr in Mar'25, while total expenditure decreased from 24.95 Cr in Mar'23 to 19.91 Cr in Mar'25. Operating profit (PBDIT) slightly decreased from 2.68 Cr in Mar'24 to 2.65 Cr in Mar'25, with profit before tax showing a decline from 1.01 Cr in Mar'24 to 0.87 Cr in Mar'25. Profit after tax also decreased from 0.77 Cr in Mar'24 to 0.58 Cr in Mar'25. The company's total assets decreased from 17.39 Cr in Mar'23 to 15.95 Cr in Mar'25,...
Read MoreWhy is Beryl Drugs falling/rising?
2025-10-29 21:39:34As of 29-Oct, Beryl Drugs Ltd's stock price is currently at Rs 24.00, reflecting an increase of Rs 1.0 or 4.35%. The stock has been gaining for the last two days, with a total return of 4.39% during this period. It has outperformed its sector by 3.61% today and reached an intraday high of Rs 27.6, which is a 20% increase. However, despite these positive movements, the stock has shown a significant year-to-date decline of 33.61% and a one-year decline of 35.12%. Additionally, there has been a notable drop in investor participation, with delivery volume falling by 69.25% against the five-day average, indicating a potential concern regarding sustained interest in the stock. Broader Market Context: In the short term, Beryl Drugs has outperformed the Sensex, with a one-week return of 7.62% compared to the benchmark's 0.68%. This indicates that while the stock is experiencing a positive momentum recently, it has...
Read MoreWhy is Beryl Drugs falling/rising?
2025-10-07 21:36:34As of 07-Oct, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at Rs 22.75, which reflects a decrease of Rs 1.24 or 5.17%. Today's price summary indicates that the stock has underperformed its sector by 5.48%, and it has fallen after three consecutive days of gains. The stock touched an intraday low of Rs 22, marking an 8.3% drop. Additionally, the delivery volume has decreased significantly, falling by 46.41% against the five-day average, suggesting a decline in investor participation. Over the longer term, the stock has seen a year-to-date decline of 37.07% and a one-year decline of 41.77%, indicating ongoing challenges. In the broader market context, Beryl Drugs' short-term performance over the past week shows a gain of 2.29%, which slightly outpaces the Sensex's increase of 2.07%. However, the stock's longer-term performance contrasts sharply with the benchmark, as it has underpe...
Read MoreWhy is Beryl Drugs falling/rising?
2025-10-06 21:27:11As of 06-Oct, Beryl Drugs Ltd is experiencing a price increase, currently at 23.99, with a change of 0.54, representing a 2.3% rise. The stock has shown strong performance recently, gaining 7.87% over the last two days and outperforming its sector by 2.19%. In terms of longer-term performance, the stock has increased by 7.82% over the past week, although it has seen a slight decline of 0.08% over the past month. Notably, the stock's delivery volume has surged by 287.03% against the five-day average, indicating rising investor participation. However, there is no information available regarding positive or negative factors that could influence the stock's movement. In the broader market context, Beryl Drugs' recent short-term return of 7.82% over the past week significantly outpaces the Sensex, which has only increased by 1.77% in the same period. This suggests that the stock is gaining traction relative to ...
Read MoreWhy is Beryl Drugs falling/rising?
2025-09-26 21:20:29As of 26-Sep, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at Rs 22.39, which reflects a decrease of Rs 1.36 or 5.73%. The stock has underperformed its sector by 3.39% today and has been on a consecutive downward trend for the last two days, accumulating a total loss of 7.44% during this period. The stock reached an intraday low of Rs 21.5, marking a significant drop of 9.47%. Over the past week, Beryl Drugs has seen a return of -1.97%, and over the past month, it has declined by 12.20%. Year-to-date, the stock has fallen by 38.06%, contrasting sharply with the Sensex, which has gained 2.93% during the same timeframe. Notably, the stock's delivery volume has plummeted by 93.96% against its five-day average, indicating a significant drop in investor participation. In the broader market context, the pharmaceuticals and drugs sector has also faced challenges, with a decline of 2.35%...
Read MoreWhy is Beryl Drugs falling/rising?
2025-09-24 21:27:36As of 24-Sep, Beryl Drugs Ltd is experiencing a price increase, with the current price at Rs 24.24, reflecting a rise of Rs 1.24 or 5.39%. The stock has shown strong performance today, outperforming its sector by 5.84% and achieving a consecutive gain over the last two days, resulting in an overall return of 8.17% during this period. Despite a wide intraday trading range and high volatility, the stock's weighted average price indicates more volume traded closer to its low price. Additionally, the stock is trading at a discount compared to its peers' average historical valuations, which contributes to its attractive valuation despite a significant decline in profits over the past year. In the broader market context, Beryl Drugs has outperformed the Sensex in the short term, with a 1-week return of +5.39% compared to the benchmark's -1.18%. However, the stock has underperformed over the longer term, with a y...
Read MoreWhy is Beryl Drugs falling/rising?
2025-09-23 21:39:50As of 23-Sep, Beryl Drugs Ltd is experiencing a price increase, currently at 23.00, with a change of 0.59 or 2.63% up. Today's performance indicates that the stock has outperformed its sector by 2.98% and has gained after two consecutive days of decline. However, despite this short-term uptick, the stock has shown a negative return of -36.11% over the past year, with profits falling by -37%. The stock is trading at a discount compared to its peers' average historical valuations, and it has a very attractive valuation with a Return on Capital Employed (ROCE) of 11. Nonetheless, the company faces challenges, including weak long-term fundamental strength and a poor EBIT to Interest ratio of 0.86, which may contribute to investor caution. In the broader market context, Beryl Drugs has underperformed compared to the Sensex, which has generated a return of -3.33% over the past year, while Beryl Drugs' return was...
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
15-Nov-2025 | Source : BSEresults publication for quarter/ half year ended 30.09.2025
Board Meeting Outcome for OUTCOME OF BOARD MEETING
13-Nov-2025 | Source : BSEOUTCOME OF BOARD MEETING
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2025
13-Nov-2025 | Source : BSEUNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2025
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






